- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Diagnostic and Therapeutic Endoscopy
Volume 2013 (2013), Article ID 250641, 5 pages
Endomicroscopic Imaging of COX-2 Activity in Murine Sporadic and Colitis-Associated Colorectal Cancer
Department of Medicine 1, University of Erlangen-Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany
Received 27 August 2012; Accepted 26 December 2012
Academic Editor: Helmut Neumann
Copyright © 2013 Sebastian Foersch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. A. Baron, B. F. Cole, R. S. Sandler et al., “A randomized trial of aspirin to prevent colorectal adenomas,” New England Journal of Medicine, vol. 348, no. 10, pp. 891–899, 2003.
- J. A. Baron, “Aspirin and cancer: trials and observational studies,” Journal of the National Cancer Institute, vol. 104, pp. 1199–1200, 2012.
- P. M. Rothwell, F. G. R. Fowkes, J. F. Belch, H. Ogawa, C. P. Warlow, and T. W. Meade, “Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials,” The Lancet, vol. 377, no. 9759, pp. 31–41, 2011.
- P. A. Janne and R. J. Mayer, “Chemoprevention of colorectal cancer,” New England Journal of Medicine, vol. 342, pp. 1960–1968, 2000.
- M. J. Waldner and M. F. Neurath, “Potential avenues for immunotherapy of colitis-associated neoplasia,” Immunotherapy, vol. 4, pp. 397–405, 2012.
- E. Bastiaannet, K. Sampieri, O. M. Dekkers, A. J. de Craen, M. P. van Herk-Sukel, and V. Lemmens, “Use of aspirin postdiagnosis improves survival for colon cancer patients,” British Journal of Cancer, vol. 106, pp. 1564–1570, 2012.
- R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 62, pp. 10–29, 2012.
- S. D. Markowitz, “Aspirin and colon cancer—targeting prevention?” New England Journal of Medicine, vol. 356, no. 21, pp. 2195–2198, 2007.
- C. E. Eberhart, R. J. Coffey, A. Radhika, F. M. Giardiello, S. Ferrenbach, and R. N. Dubois, “Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas,” Gastroenterology, vol. 107, no. 4, pp. 1183–1188, 1994.
- C. S. Williams, C. Luongo, A. Radhika et al., “Elevated cyclooxygenase-2 levels in Min mouse adenomas,” Gastroenterology, vol. 111, no. 4, pp. 1134–1140, 1996.
- J. Cuzick, F. Otto, J. A. Baron et al., “Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement,” The Lancet Oncology, vol. 10, no. 5, pp. 501–507, 2009.
- M. Goetz and R. Kiesslich, “Advances of endomicroscopy for gastrointestinal physiology and diseases,” American Journal of Physiology, vol. 298, no. 6, pp. G797–G806, 2010.
- H. Neumann, R. Kiesslich, M. B. Wallace, and M. F. Neurath, “Confocal laser endomicroscopy: technical advances and clinical applications,” Gastroenterology, vol. 139, no. 2, pp. 388–392, 2010.
- M. Goetz, A. Ziebart, S. Foersch et al., “In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor,” Gastroenterology, vol. 138, no. 2, pp. 435–446, 2010.
- S. Foersch, R. Kiesslich, M. J. Waldner, P. Delaney, P. R. Galle, and M. F. Neurath, “Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy,” Gut, vol. 59, pp. 1046–1055, 2010.
- M. J. Uddin, B. C. Crews, A. L. Blobaum et al., “Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents,” Cancer Research, vol. 70, no. 9, pp. 3618–3627, 2010.
- C. Neufert, C. Becker, and M. F. Neurath, “An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression,” Nature Protocols, vol. 2, no. 8, pp. 1998–2004, 2007.
- M. Goetz and T. D. Wang, “Molecular imaging in gastrointestinal endoscopy,” Gastroenterology, vol. 138, no. 3, pp. 828–833, 2010.
- F. Mariani, P. Sena, L. Marzona et al., “Cyclooxygenase-2 and Hypoxia-Inducible Factor-1α protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis,” Cancer Letters, vol. 279, no. 2, pp. 221–229, 2009.
- K. Tatsu, S. Hayashi, I. Shimada, and K. Matsui, “Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis,” Pathology Research and Practice, vol. 201, no. 6, pp. 427–433, 2005.
- K. M. Sheehan, F. O'Connell, A. O'Grady et al., “The relationship between cyclooxygenase-2 expression and characteristic of malignant transformation in human colorectal adenomas,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 6, pp. 619–625, 2004.
- S. Kanaoka, K. I. Yoshida, N. Miura, H. Sugimura, and M. Kajimura, “Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening,” Gastroenterology, vol. 127, no. 2, pp. 422–427, 2004.
- A. Castells, A. Payá, C. Alenda et al., “Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency,” Clinical Cancer Research, vol. 12, no. 6, pp. 1686–1692, 2006.
- A. T. Chan, S. Ogino, and C. S. Fuchs, “Aspirin and the risk of colorectal cancer in relation to the expression of COX-2,” New England Journal of Medicine, vol. 356, no. 21, pp. 2131–2142, 2007.